PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for locali

Nicholas John Van As

177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castrationresistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).

Michael S Hofman

Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Rana R. McKay

Molecular determinants associated with long-termresponse to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Felix Y Feng

Final results from ACIS, a randomized, placebo (PBO)-controlled doubleblind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versusAAPin patients (pts) with chemo-naivemetastatic castration-resistant prostate cancer (mCRPC)

Dana E. Rathkopf

KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

Leonard Joseph Appleman

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Kim N. Chi

CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-na¨ıve metastatic castration-resistant prostate cancer.

KarimFizazi

PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

Johann S. De Bono

Genomic landscape of advanced prostate cancer in racial minority populations: Real-world experience in a safety-net hospital oncology clinic.

Tamer Khashab

Prospective randomized trial of gene expression classifier utility following radical prostatectomy (G-MINOR).

Todd Matthew Morgan

Prevalence of microsatellite instability and monitoring response to immune checkpoint inhibition utilizing liquid biopsy among African American men with advanced prostate cancer.

Tamer Khashab

Multi-institutional evaluationof the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC).

Meredith MI Freeman

Analysis of germline alterations and testing patterns in Hispanic men with prostate cancer.

Justin Shaya

Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center.

Hala Borno

Racial disparities in efficacy of first-line abiraterone in metastatic castrateresistant prostate cancer (mCRPC).

Mallika Marar

Prescribing patterns in patients with metastatic castrate-sensitive prostate cancer (mCSPC).

Nataliya Mar

Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.

Mark Lythgoe

Effect of healthcare systemon prostate cancer-specificmortality in African American and non-Hispanic white men.

Daniella Klebaner

Association between travel distance and use of postoperative radiation therapy among men with organ-confined prostate cancer: Does geography influence treatment decisions?

Melaku A Arega

Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.

Hanna Tukachinsky

Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.

Kim N. Chi

Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.

Nobuaki Matsubara

Barriers and facilitators of germline genetic evaluation for prostate cancer.

Stacy Loeb

Use of 18F-fluciclovine PET/CT (FluPET) for prostate cancer (PC): Initial results from a prospective registry at a tertiary academic center.

Risa Liang Wong

Impact of PSMA PET/CT on SRT planning: Preliminary results from the randomized phase III trial NCT03582774.

Jeremie Calais

Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC.

Ivan de Kouchkovsky

A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.

Jeremy C. Durack

PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

Frederic Pouliot

Diagnostic utility of (18)f-fluciclovine positron emission tomography (FACBC) in biochemically recurrent (BCR) prostate cancer (PCa) based on prior primary treatment modality for localized disease and the impact of FACBC findings on treatment selection.

Marina Nasrin Sharifi

68Ga-PSMA expression changes on PET/CT for response assessment during taxane-based chemotherapy in metastatic prostate cancer patients.

Qaid Shagera

18F-DCFPyL PSMA PET imaging compared to conventional imaging in the detection of pelvic nodal metastases in patients with locally advanced or oligometastatic prostate cancer.

Ashanda Rosetta Patrice Esdaille

Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study.

Daniel Kwon

Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies.

Hala Borno

Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).

Matthew D Tucker

Time trends of drug specific adverse events among patients on androgen receptor antagonists: Implications for remote monitoring.

Lauren Fleshner

The role of androgen deprivation therapy on the clinical course of COVID- 19 infection in men with prostate cancer.

Vaibhav G. Patel

Symptom burden, functional status, and clinical outcomes of hospitalized patients with advanced genitourinary cancers.

Daniel E Lage

The real-world benefit of novel androgen receptor-targeting agents (ARTA) before and after docetaxel in CRPC with bone metastases in Japan: A subanalysis of the PROSTAT-BSI, a prospective observational study before and after approval of novel ARTAs.

Atsushi Mizokami

Medication adherence among prostate cancer patients using advanced oral therapies.

Dominic Pilon

A longitudinal study for the effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy.

Shingo Hatakeyama

Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

tephen J. Freedland

Real-world utilization of docetaxel among men with de novo metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.

Bobby Shayegan

Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castrationresistant prostate cancer (mCRPC) that progressed after first-line NAH.

Oliver A. Sartor

Genomic/genetic testing patterns for patients with metastatic castrateresistant prostate cancer: Results from a real-world study in the United States.

Andrea Leith

Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.

Christopher J.D. Wallis

Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).

Richard Gagnon

Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of treatment response to novel hormones in metastatic castrate-resistant prostate cancer: Real-world data from a single institution.

Emily Scott

Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.

Daniel M. Geynisman

Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.

Morgan Goujon

Quality of life of prostate cancer (PCa) patients aged 60 years and older: Changes in QLQ-ELD14 dimensions after a six-month gonadotropinreleasing hormone agonist (GnRHa) therapy, according to age groups–Primary analysis of PRISME study.

Francois Rozet

Cognitive status of prostate cancer (PCa) patients aged 60 years and older after a six-month gonadotropin-releasing hormone agonist (GnRHa) therapy, according to age groups: Secondary analysis of PRISME study.

Morgan Roupret

Sequence decision making for cabazitaxel (Cbz) versus abiraterone (Abt) or enzalutamide (Enz) post-docetaxel (Dtx) in a publicly funded health care system.

Alexander Watson

Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function.

Shilpa Gupta,

Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.

Umang Swami

Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415.

Rahul Ramesh Khairnar

Clinically significant events associated with metastatic castrationresistant prostate cancer (mCRPC) treatments.

Kelvin A. Moses

Comparative cardiotoxicity of the novel hormonal agents abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data.

Jason Hu

The potential role of frailty in modifying quality-of-life related outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel, abiraterone, enzalutamine, and radium 223.

Seungyeon Kim

Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Andrey Soares

Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men.

Minh-Phuong Huynh-Le

Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.

Barry Tong

The contribution of germline DNA damage response mutations on prostate cancer risk and prognosis: A UK Biobank whole-exome analysis.

Niedzica Camacho

Use of bone modifying agents in patients with metastatic castratesensitive prostate cancer.

Aaron Philip Mitchell

Comparative analysis of sarcopenia induced by long-term abiraterone (A) versus enzalutamide (E) therapy in men with metastatic castrationresistant prostate cancer (mCRPC).

Mahdi Farzad Naimi

Evaluating financial burdens of oral hormonal therapies for patients with prostate cancer.

Eric B Schwartz

Referral patterns and treatment preferences in patients with advanced prostate cancer (aPC): Differences between medical oncologists and urologists.

Ajeet Gajra

Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC).

Andrew Warren Hahn

Cardiac risk factors and events in patients with prostate cancer commencing androgen deprivation therapy: Analysis from a tertiary care center in the Middle East.

Mona Hassan

Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.

Ashanda Rosetta Patrice Esdaille

The effects of bright white light therapy on obese frailty in older men with prostate cancer on hormonal therapy: A pilot randomized control trial.

Cristiane Decat Bergerot

Impact of treatment and frailty on elder-relevant physical function outcomes in older adults with metastatic castration-resistant prostate cancer (mCRPC).

Helen Yang

A phase II study to evaluate the effects of docetaxel plus lycopene in advanced castrate-resistant prostate cancer.

Eric Zhuang

Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model.

William R. Moore

Rucaparib plus enzalutamide in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.

Arpit Rao

Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).

Wassim Abida

Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB.

Hiroji Uemura

Outcomes of older men receiving docetaxel for metastatic hormonesensitive prostate cancer.

Daniel E Lage

Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynA

Paul Vincent Viscuse

PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.

Ugo De Giorgi

A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Neal D. Shore

ICEPAC: A phase II multicenter study of avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castrationresistant prostate cancer (mCRPC).

Arun Azad

PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).

Jodi Lyn Layton

Relationship between changes in serum androgen level measured by LCMS/MS and therapeutic effect after enzalutamide treatment.

Yoshiyuki Miyazawa

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

Landon Carter Brown

Interim analysis of STARTAR:Aphase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical

Tian Zhang

Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer:A new user design in the French nationwide claims database.

Marine Gross-Goupil

Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).

Vincent Chau

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castrationresistant prostate cancer (mCRPC).

Johann S. De Bono

Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).

Maha H. A. Hussain

Phase I study of entinostat in combination with enzalutamide for treatment of patients with castration-resistant prostate cancer.

Jianqing Lin

Cabazitaxel multiple rechallenge in metastatic castration-resistant prostate cancer: Atherapeutic option to increase overall survival?

Cedric Pobel

Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

Atish Dipankar Choudhury

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects withmCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).

Nicholas J. Vogelzang

Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).

Fadi Taza

Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).

Tomasz M. Beer

Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

Arun Azad

Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial).

Sarennya Pathmanandavel

In vitro and in vivo investigations of novel 1,4-napthoquinone sulphomethylene carbohydrate conjugates in prostate cancer.

Tobias Busenbender

Synergistic antitumor efficacy of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft model.

Mari I Suominen,

Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.

Daniel J. George

SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castraterefractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.

Robert J. Jones

A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).

Tie Zhou

A multicenter retrospective analysis examining the effect of dipeptidyl protease 4 (DPP4) inhibitors on progression-free survival in patients with prostate cancer.

Kelsey Pan

Prevalence of oligoprogression in metastatic hormone-resistant prostate cancer patients on androgen targeted therapies: Could targeted radiotherapy improve patient outcomes?

Priyanka Patel

Local prostate radiotherapy in metastatic prostate cancer and symptomatic local events.

Jaime Kirsten Kwok

Phase II study of the efficacy of abirateron acetate with dutasteride for castration-resistant prostate cancer.

Hideyasu Matsuyama

A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.

Brandon Lau

OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oligometastatic prostate cancer—A phase II trial.

Tobias Hölscher

Preliminary results from a phase II trial of docetaxel before castration with degarelix in men with newly diagnosed metastatic prostate cancer.

Theodore Stewart Gourdin

UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.

Mary Mahler

ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensiv

Giulio Francolini

Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.

Ronan Le Moigne

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Justin M Lebenthal

Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.

Victoria Brennan

Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy.

Michael J. Morris

Salvage chemotherapywith cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.

Gunhild Von Amsberg

BXCL701, first-in-class oral activator of systemic innate immunity pathway, combinedwith pembrolizumab (Keytruda) in menwith metastatic castrationresistant prostate cancer (mCRPC).

Rahul Raj Aggarwal

A phase I clinical trial of PSMA-directed/TGFb-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

Vivek Narayan

Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Johann S. De Bono

Molecular and clinical characterization of metastatic castration-resistant prostate cancer (mCRPC) patients achieving deep PSA responses to bipolar androgen therapy (BAT).

Mark Christopher Markowski

Temporal trends and predictors in diagnosing pathologic node-positive prostate cancer in clinically node-negative patients.

Ryan Hutten

Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer: An exploratory analysis.

Saurav Verma

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer, chemo-naive, who received a prior diethylstilbestrol therapy.

Diogo Assed Bastos

Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

Mark Christopher Markowski

Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castrationresistant prostate cancer (mCRPC).

Ulka N. Vaishampayan

Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).

Juan Rodrigo Briones Carvajal

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.

Adam Kessel

Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence.

Lawrence Mbuagbaw

Associations of circulating cell-free DNA (cfDNA) and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC).

Daniel H. Shevrin

ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC.

Ellen Jaeger

Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castrationresistant prostate cancer (mCRPC).

Jones T. Nauseef

Combining molecular and functional imaging in metastatic castrationresistant prostate cancer (mCRPC).

Vincenza Conteduca

Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).

Ryon Graf

Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.

Rachel Sabol

Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients.

Paula Kappler

Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory,metastatic castration-resistant prostate cancer (mCRPC).

Stefan Brunotte

Baseline pathogenic mutations in non-AR/non-TP53 genes and prediction of response to high-dose testosterone.

Ellen Jaeger

Gut microbiota-associated compounds increase lethal prostate cancer risk.

Bryan Douglas Naelitz

5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.

Martin Sjöström

Prognostic association between common laboratory tests and overall　survival in men with de novo metastatic castration-sensitive prostate cancer: A population-based study.

Shawn Malone

The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone-sensitive prostate cancer.

Justin Shaya

SPOP mutations in prostate cancer: Clinical and genomic features.

Mari Nakazawa

Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project.

Nobuaki Matsubara

p2PSA-associated parameters are significant predictors of reclassification of first-year protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study.

Takuma Kato

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B)

Susan Halabi

Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).

Khobe Chandran

Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients.

Pedro C. Barata

Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

Howard I. Scher

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) inmenwith metastatic castration-resistant prostate cancer (mCRPC).

Michael Sun

Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.

Edmond Michael Kwan

SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.

Andrew Stangl

CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

Johann S. De Bono

Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) withBRCA1 versusBRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).

Raquel Reisinger

HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.

Petros Grivas

Differential levels of serum PSA related to volume of benign, Gleason pattern 3 and pattern 4 prostate tissue.

Ciro Andolfi

Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).

Petros Grivas

Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.

Taylor Ryan McFarland

Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.

Jasmine Jiemei Wang

Genomic characterization and molecular taxonomy of sarcomatoid variant prostate cancer.

Mary Duong

The effect of statins on overall survival and progression-free survival in veterans with prostate cancer: A retrospective single-center experience.

Brian Warnecke

Addressing financial toxicity in urologic oncology patients.

Divya Ahuja Parikh

18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.

Pedro C. Barata

Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245

Jeremie Calais

Treatment of aggressive prostate cancers in real life: Initiation, schedule, and management of triptorelin treatment (TALISMAN)—Design of the study.

Thierry Lebret

phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatorybispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.

Jingsong Zhang

Fractionated docetaxel and radium-223 (Ra223) in metastatic castrationresistant prostate cancer (CRPC): A phase I trial.

Brendan James Connell

AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive

Dana E. Rathkopf

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

Louise Emmett

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Karim Fizazi

INNOVATE (NRG-GU008):Arandomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

Ronald C. Chen

UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).

Arun Azad

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Arpit Rao

A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Justin Shaya

Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

William Kevin Kelly

Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) withmetastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.

Christian Gratzke

Open-label, phase II study of ladiratuzumab vedotin (LV) for castrationresistant prostate cancer (SGNLVA-005, trial-in-progress).

Amna Falak Sher

A phase II study of onvansertib in combination with abiraterone and prednisone in patients withmetastatic castration-resistant prostate cancer (mCRPC).

David Johnson Einstein

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-a

A. Oliver Sartor

A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Michael Sun

PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.

Wassim Abida

A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal

Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).

Omer Kucuk

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Dhruv Bansal

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold-standard.

Ida Sonni

Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial.

Pirus Ghadjar

Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.

Jonathan David Tward

PSA velocity to predict clinical progression in African American and non- Hispanic White patients with low-risk prostate cancer undergoing active surveillance.

Juan Javier-Desloges

An FDA pooled analysis: Characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and/or radiation therapy.

Jaleh Fallah

The association between sexual orientation and screening of prevalent gender-specific cancers.

Michael Joseph Herriges

Factors influencing noncompletion of radiotherapy among men with localized prostate cancer.

Edward Christopher Dee

The impact of telemedicine on patient-reported outcomes in urologic oncology.

Adam John Gadzinski

Racial disparities in depression incidence, management, and mortality after prostate cancer diagnosis.

Ravi Bharat Parikh

Understanding racial disparities in survival among U.S. veterans with localized high-risk prostate cancer, 2004-2019.

Ravi Bharat Parikh

Care received by rural and urban patients with newly diagnosed prostate cancer: Results from a population-based prospective cohort.

Xinglei Shen

Utilization and survival outcomes between definitive versus conservative treatments among elderly men with high-risk prostate cancer.

Sagar Anil Patel

Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.

David Dewei Yang

Considerations for active surveillance in select Gleason grade group 2 patients: A preliminary study.

Jillian Egan

Bilateral disease and risk of prostate cancer progression in an active surveillance cohort.

Nabila Khondakar

MRI-guided fusion biopsy of the prostate resection bed among post-radical prostatectomy patients with rising PSA.

Cheyenne Williams

Multimodal biomarkers overcome sampling bias to predict presence of aggressive localized prostate cancer.

David Monty Berman

Pinpointing uncharacterized prostate cancer in active surveillance patients through mpMRI biopsy.

Jacob W. Greenberg

Myocardial perfusion PET imaging to evaluate coronary microvascular dysfunction in men with prostate cancer receiving androgen deprivation therapy.

Vivek Narayan

Clinical significance of the sonazoid-enhanced ultrasound for prostate cancer.

Jun Akatsuka

Management of localized prostate cancer during the Covid-19 pandemic at a multidisciplinary cancer center in New York City, New York.

Andrew Wood

Evaluating the correlation between early and late quality-of-life declines using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) after definitive stereotactic body radiotherapy, intensitymodulated radiotherapy, or brachytherap

Jacob Samuel Parzen

Financial toxicity and patient-provider communication about cancerrelated cost among prostate cancer patients and survivors.

Elissa C. Kranzler

Radical prostate radiotherapy and the use of androgen deprivation in the era of risk stratification: Does real-world practice follow the evidence?

Mark Prentice

Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.

Shan Jiang

Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.

Eric Margolis

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up.

Michael Austin Brooks

Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort.

Geraldine Pignot

Visual analogue scales (VAS) as exploratory evaluation of eight dimensions in prostate cancer (PCa) patients aged 60 years and older initiating a gonadotropin-releasing hormone agonist (GnRHa) therapy: Secondary analysis of PRISME study.

Christophe Hennequin

Conditional progression-free survival in men on active surveillance for prostate cancer stratified by NCCN risk.

Andrew Gusev

Hospital efficiency and quality of prostate cancer care.

Ravishankar Jayadevappa

Effectiveness of early diagnosis for prostate cancer based on PSA and multiparametric MRI: A simulation study.

Marc-Olivier Timsit

The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer.

Adam Schneider

Impact of 5-ALPHA reductase inhibitor use on prostate cancer risk at the time of urology referral.

James T Kearns

The BARCODE1 pilot study targeting men with increased genetic risk of developing prostate cancer: Examining the feasibility of a communitybased screening program using polygenic risk score to target screening.

Jana Kathlyn McHugh

Association of reductions in PSA screening across states with increased metastatic prostate cancer in the United State.

Vidit Sharma

High-risk nonmetastatic prostate cancer in the elderly: Does adjuvant chemotherapy affect survival?

Komal Akhtar

Impact of inflammatory bowel disease on radical prostatectomy outcomes and costs of care.

Ilana Goldberg

Risk of urinary morbidity associated with photoselective vaporization of the prostate (PVP) in prostate cancer patients undergoing a combined radiotherapy regimen consisting of dynamic adaptive radiotherapy (DART) and brachytherapy boost.

Michael J. Dattoli

Incidence and cost of radical prostatectomy for NCCN low-risk prostate cancer in Utah.

David Michael Gill

Systematic review of time to definitive treatment for intermediate-risk and high-risk prostate cancer: Are delays associated with worse outcomes?

David-Dan Nguyen

The positive impact of implementing an onsite guideline-based genetic testing procedure for prostate cancer in a multidisciplinary uro-oncology clinic.

Siddharth Ramanathan

Hospital competition, quality, and cost of prostate cancer care.

Ravishankar Jayadevappa

Timing of high-dose rate brachytherapy with external beam radiotherapy in intermediate and high-risk localized prostate cancer (THEPCA) patients and its effects on toxicity and quality of life: Results of a randomized feasibility trial.

Imtiaz Ahmed

Intraprostatic calcification and biochemical recurrence in men treated with Cs-131 prostate brachytherapy.

Michael D Schad

Post-radical prostatectomy (RP) outcome for patients with high-risk prostate cancer treated with intense neoadjuvant hormone therapy (NHT): Results of a pooled analysis of contemporary clinical trials.

Rana R. McKay

Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.

Matthew Raymond Smith

Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.

Neal D. Shore

Early surrogate measures for ablative therapies for intermediate-risk prostate cancer patients.

Rachel Glicksman

Analysis of rectal dose during prostate stereotactic body radiotherapy in MR-guided radiotherapy.

Kobika Sritharan

Neoadjuvant versus concurrent androgen deprivation therapy plus radiotherapy for unfavorable intermediate-risk and high-risk prostate cancer with low PSA.

Neal Andruska

Sixty-day unplanned readmissions after robot-assisted versus openradical prostatectomy.

Prasanth Lingamaneni

Normal tissue complication probabilities (NTCP) of urethral stricture following salvage SBRT or HDR for periurethral recurrences following prior definitive radiation therapy.

Russell Injerd

Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.

Bruce J. Trock

The stereotactic prostate radiotherapy (SPORT) trial: A randomized feasibility study comparing prostate SABR to prostate and pelvic nodal SABR.

Ciaran Fairmichael

Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.

Wei Loong Sherman Yee

Significance of targeting the antiapoptotic pathway in castrationsensitive prostate cancer.

Goutam Chakraborty

Immunohistochemical evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters.

Zin Myint

The effect of maximum tumor diameter on disease control in intermediate and high-risk prostate cancer patients treated with brachytherapy boost.

Matthew Parsons

Localized activation of the metastatic phenotype within the perineural region in prostate cancer.

Mick D. Brown

Single-cell analysis of cellular state heterogeneity in human localized prostate cancer.

Hanbing Song

Impact of early hypothalamic-pituitary-gonadal axis maturation on prostate cancer: Cross-sectional analysis of a Veterans Affairs cohort.

Rimaz M. Khadir

Real-world prevalence of homologous recombination repair gene (BRCA1/2and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).

Nicolas Sayegh

Lower risk of prostate cancer in patients with sedentary occupations presenting for a prostate biopsy: Analysis of a Veterans Affairs cohort.

Rimaz M. Khadir

Genomic analysis for active surveillance to predict upstaging after prostatectomy.

Andrea Quinn

Stage at presentation and oncologic outcomes for agent orange exposed and non-exposed United States veterans diagnosed with prostate cancer.

Alexander Tward

Patterns of care and treatment outcomes in locoregional squamous cell carcinoma of the prostate.

Christopher Weil

Extraperitoneal versus transperitoneal approach for robot-assisted radical prostatectomy: An updated systematic review and meta-analysis.

Michael Uy

A single-blinded, multicenter, randomized controlled trial to evaluate NeuroSAFE robotic-assisted radical prostatectomy (RARP) versus standard robotic-assisted radical prostatectomy (RARP) in men with localized prostate cancer: NeuroSAFE PROOF—Trial in pr

Eoin Dinneen

A phase I, dose-expansion cohort study on the safety of a cannabidiol for biochemical recurrence in prostate cancer patients.

Zin Myint

Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).

Omar Alghazo

A multi-institutional phase I/II trial of focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer in patients treated with prior radiotherapy (F-SHARP).

Abhishek A Solanki

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salva

Tamim Niazi

PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).

Neha Vapiwala